10/13/2025

Recent Oncology Related FDA Approvals and Expanded Indications

FDA Approves Regeneron's Libtayo® (cemiplimab-rwlc) for Adjuvant Treatment of Adults with Cutaneous Squamous Cell Carcinoma (CSCC)

FDA Approves Jazz Pharmaceutical's Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer in Adults

FDA Approves Lilly's Inluriyo (imlunestrant) for the Treatment of Adults With ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

More Info